Answers are grounded in this paper and cite their sources.
Follicular lymphoma (FL) is an indolent neoplasm originating from B-lymphocytes and is characterized by slow growth, excellent response to therapy, and a relapsing remitting course. Despite the fact that FL is still considered an incurable disease, the natural history of their disease has dramatically improved during the last years and is now measured in decades, reducing the impact of FL diagnosis on life expectancy. This is the result of a combination of the unaggressive biology of FL and of the availability of highly effective therapies. In the context of a relapsing remitting neoplasm, every line of therapy adds efficacy to the therapeutic strategy adopted for each patient. The therapeutic decision taken in newly diagnosed FL patients, however, is “more critical” than other lines because it is associated with the best results in terms of response rates and time to progression and might also act on subsequent risks (i.e., histologic transformation, late toxicity, chemoresistance). Most importantly, in a significant proportion of patients, first-line therapy could be the only treatment FL patients receive in their lifetime. It is thus very important to understand the pros and cons of available alternative options for the initial management of FL to optimize medical intervention. In this review article we summarize the recent evidence about upfront therapy for FL, comparing the most rooted evidence and considering new perspectives.
No takes yet. Share an insight, caveat, or question.
Luminari et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: